Allysta doses first patient in phase 1/2a dry eye trial

The first patient has been dosed in a phase 1/2a trial of ALY688, a dry eye treatment candidate, Allysta Pharmaceuticals announced in a press release.

A novel peptide agonist that binds to and activates adiponectin receptors, ALY688 acts to reduce inflammation and promote healing of the cells lining the ocular surface, the release said.

“This marks a significant milestone for Allysta, as we now progress from a preclinical into a clinical-stage company. We look forward to completing this trial by mid-year and reporting data in the second half of 2020,” Henry Hsu, MD, CEO and president of Allysta, said in the release.

The first patient has been dosed in a phase 1/2a trial of ALY688, a dry eye treatment candidate, Allysta Pharmaceuticals announced in a press release.

A novel peptide agonist that binds to and activates adiponectin receptors, ALY688 acts to reduce inflammation and promote healing of the cells lining the ocular surface, the release said.

“This marks a significant milestone for Allysta, as we now progress from a preclinical into a clinical-stage company. We look forward to completing this trial by mid-year and reporting data in the second half of 2020,” Henry Hsu, MD, CEO and president of Allysta, said in the release.